# Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

> **NCT03541928** · PHASE2 · UNKNOWN · sponsor: **The Methodist Hospital Research Institute** · enrollment: 60 (estimated)

## Conditions studied

- High-risk Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** HSV-Tk
- **DRUG:** Valacyclovir
- **DRUG:** Bicalutamide
- **DRUG:** Leuprolide Acetate
- **RADIATION:** Brachytherapy, External beam radiotherapy
- **PROCEDURE:** Radical prostatectomy

## Key facts

- **NCT ID:** NCT03541928
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-02
- **Primary completion:** 2023-07
- **Final completion:** 2023-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541928, "Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03541928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*